中医药治疗非酒精性脂肪性肝病的重要靶位——肠道微生态

李红山; 胡义扬

doi:10.3969/j.issn.1001-5256.2020.01.002

中医药治疗非酒精性脂肪性肝病的重要靶位——肠道微生态

DOI: 10.3969/j.issn.1001-5256.2020.01.002

1. 上海中医药大学肝病研究所
2. 中国科学院大学宁波华美医院
3. 宁波大学医学院
4. 上海中医药大学附属曙光医院临床研究中心

基金项目:

国家自然科学基金重点项目(81830119);国家自然科学基金面上项目(81873109)；上海市申康行动三年计划项目(16CR1019A)；

详细信息

中图分类号: R259
计量
- 文章访问数: 1425
- HTML全文浏览量: 50
- PDF下载量: 300
- 被引次数: 0
出版历程
- 收稿日期: 2019-09-12
- 出版日期: 2020-01-20

Gut microecology: An important target of traditional Chinese medicine in the treatment of nonalcoholic fatty liver disease

Institute of Liver Diseases,Shanghai University of Traditional Chinese Medicine

Research funding:

摘要

摘要: 肠道微生态在非酒精性脂肪性肝病发病机制中具有重要意义。系统阐释非酒精性脂肪性肝病与肠道菌群、肠道菌代谢物和肠屏障功能关系,结合中医药调节肠道微生态与治疗非酒精性脂肪性肝病关系的研究概况,提出调节肠道微生态、维持肠道稳态是中医药治疗非酒精性脂肪性肝病的重要策略。
- 非酒精性脂肪性肝病 /
- 中医学 /
- 胃肠道微生物组
Abstract: Gut microecology plays an important role in the pathogenesis of nonalcoholic fatty liver disease. With reference to the research on traditional Chinese medicine in regulating gut microecology and treating nonalcoholic fatty liver disease,this article systematically elaborates on the association of nonalcoholic fatty liver disease with intestinal flora,gut bacterial metabolites,and gut barrier function and points out that the regulation of gut microecology and the maintenance of intestinal homeostasis are important measures for traditional Chinese medicine in the treatment of nonalcoholic fatty liver disease.
- non-alcoholic fatty liver disease /
- TCM science /
- gastrointestinal microbiome

HTML全文

参考文献(46)

[1] FLOCH MH. Intestinal microecology in health and wellness[J]. J Clin Gastroenterol,2011,45(Suppl):s108-s110.

[2] WANG W,LI X,YAO X,et al. The characteristics analysis of intestinal microecology on cerebral infarction patients and its correlation with apolipoprotein E[J]. Medicine(Baltimore),2018,97(41):e12805.

[3] WU C,OUYANG M,GUO Q,et al. Changes in the intestinal microecology induced by bacillus subtilis inhibit the occurrence of ulcerative colitis and associated cancers:A study on the mechanisms[J]. Am J Cancer Res,2019,9(5):872-886.

[4] LIN S,WANG Z,LAM KL,et al. Role of intestinal microecology in the regulation of energy metabolism by dietary polyphenols and their metabolites[J]. Food Nutr Res,2019,14:63.

[5] EZZAIDI N,ZHANG X,COKER OO,et al. New insights and therapeutic implication of gut microbiota in non-alcoholic fatty liver disease and its associated liver cancer[J]. Cancer Lett,2019,459:186-191.

[6] QIN J,LI R,RAES J,et al. A human gut microbial gene catalogue established by metagenomic sequencing[J]. Nature,2010,464(7285):59-65.

[7] WANG J,LANG T,SHEN J,et al. Core gut bacteria analysis of healthy mice[J]. Front Microbiol,2019,10:887.

[8] SCHWENGER KJP,BOLZON CM,LI C,et al. Non-alcoholic fatty liver disease and obesity:The role of the gut bacteria[J]. Eur J Nutr,2019,58(5):1771-1784.

[9] FIALHO A,FIALHO A,THOTA P,et al. Small intestinal bacterial overgrowth is associated with non-alcoholic fatty liver disease[J]. J Gastrointestin Liver Dis,2016,25(2):159-165.

[10] KAPIL S,DUSEJA A,SHARMA BK,et al. Small intestinal bacterial overgrowth and toll-like receptor signaling in patients with non-alcoholic fatty liver disease[J]. J Gastroenterol Hepatol,2016,31(1):213-221.

[11] ROY TL,LLOPIS M,LEPAGE P,et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice[J]. Gut,2013,62(12):1787-1794.

[12] RUIRUI W,HUI L,XIN Y,et al. Genetically obese human gut microbiota induces liver steatosis in germ-free mice fed on normal diet[J]. Front Microbiol,2018,9:1602.

[13] DING Y,YANAGI K,CHENG C,et al. Interactions between gut microbiota and non-alcoholic liver disease:The role of microbiota-derived metabolites[J]. Pharmacol Res,2019,141:521-529.

[14] JIAO N,BAKER SS,CHAPA-RODRIGUEZ A,et al. Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD[J]. Gut,2017,152(5):s1068.

[15] ARAB JP,KARPEN SJ,DAWSON PA,et al. Bile acids&nonalcoholic fatty liver disease:Molecular insights and therapeutic perspectives[J]. Hepatology,2017,65(1):350-362.

[16] GU M,ZHAO P,ZHANG S,et al. Betulinic acid alleviates endoplasmic reticulum stress-mediated nonalcoholic fatty liver disease through activation of farnesoid X receptors in mice[J]. Br J Pharmacol,2019,176(7):847-863.

[17] FIORUCCI S,DISTRUTTI E. Bile acid-activated receptors,intestinal microbiota,and the treatment of metabolic disorders[J]. Trends Mol Med,2015,21:702-714.

[18] ZHANG DY,ZHU L,LIU HN,et al. The protective effect and mechanism of the FXR agonist obeticholic acid via targeting gut microbiota in non-alcoholic fatty liver disease[J]. Drug Des Devel Ther,2019,13:2249-2270.

[19] HUIKUAN C,YI D,LING Y,et al. Small metabolites,possible big changes:A microbiota-centered view of non-alcoholic fatty liver disease[J]. Gut,2019,68(2):359-370.

[20] CHAMBERS ES,VIARDOT A,PSICHAS A,et al. Effects of targeted delivery of propionate to the human colon on appetite regulation,body weight maintenance and adiposity in overweight adults[J]. Gut,2015,64(11):1744-1754.

[21] SCHWIERTZ A,TARAS D,SCHFER K,et al. Microbiota and SCFA in lean and overweight healthy subjects[J]. Obesity(Silver Spring),2010,18(1):190-195.

[22] ZHOU D,PAN Q,LIU XL,et al. Clostridium butyricum B1 alleviates high-fat diet-induced steatohepatitis in mice via enterohepatic immunoregulation[J]. J Gastroenterol Hepatol,2017,32(9):1640-1648.

[23] LIANG Y,LIN C,ZHANG Y,et al. Probiotic mixture of Lactobacillus and Bifidobacterium alleviates systemic adiposity and inflammation in non-alcoholic fatty liver disease rats through Gpr109a and the commensal metabolite butyrate[J]. Inflammopharmacology,2018,26(4):1051-1055.

[24] SELLMANN C,BAUMANN A,BRANDT A,et al. Oral supplementation of glutamine attenuates the progression of nonalcoholic steatohepatitis in C57BL/6J mice[J]. J Nutr,2017,147(11):2041-2049.

[25] LIN Z,CAI F,LIN N,et al. Effects of glutamine on oxidative stress and nuclear factor-κB expression in the livers of rats with nonalcoholic fatty liver disease[J]. Exp Ther Med,2014,7(2):365-370.

[26] SELLMANN C,DEGEN C,JIN CJ,et al. Oral arginine supplementation protects female mice from the onset of non-alcoholic steatohepatitis[J]. Amino Acids,2017,49(7):1215-1225.

[27] JEGATHEESAN P,WALIGORADUPRIET AJ,NUBRET E,et al. Effect of specific amino acids on hepatic lipid metabolism in fructose-induced non-alcoholic fatty liver disease[J].Clin Nutr,2016,35(1):175-182.

[28] GIORGIO V,MIELE L,PRINCIPESSA L,et al. Intestinal permeability is increased in children with non-alcoholic fatty liver disease,and correlates with liver disease severity[J]. Dig Liver Dis,2014,46(6):556-560.

[29] ALISI A,MANCO M,DEVITO R,et al. Endotoxin and plasminogen activator inhibitor-1 serum levels associated with nonalcoholic steatohepatitis in children[J]. J Pediatr Gastroenterol Nutr,2010,50(6):645-649.

[30] ZHOU X,HAN D,XU R,et al. A model of metabolic syndrome and related diseases with intestinal endotoxemia in rats fed a high fat and high sucrose diet[J]. PLo S One,2014,9(12):e115148.

[31] LI HS,FENG Q,ZHU DD,et al. Clinical observation on Qushi Huayu Decoction for 82 cases of non-alcoholic steatohepatitis with phlegm-stasis accumulation syndrome[J]. Chin Arch Tradit Chin Med,2013,31(8):1764-1767.(in Chinese)李红山，冯琴，朱德东，等．祛湿化瘀方治疗痰瘀互结型非酒精性脂肪性肝炎临床观察[J]．中华中医药学刊，2013,31(8):1764-1767.

[32] LI HS,FENG Q,ZHU DD,et al. Effects and mechanisms of Qushi Huayu Decoction on serum free fatty acid in patients with non-alcoholic steatohepatitis[J]. Chin Arch Tradit Chin Med,2013,31(7):1640-1642.(in Chinese)李红山，冯琴，朱德东，等．祛湿化瘀方对非酒精性脂肪性肝炎患者血清游离脂肪酸的作用及机制研究[J]．中华中医药学刊，2013,31(7):1640-1642.

[33] LI HS,FENG Q,ZHU DD,et al. Dynamic changes of leptin in patients with non-alcoholic steatohepatitis and its intervetion by chinese herbal decoction[J]. Chin Arch Tradit Chin Med,2013,31(9):1962-1964.(in Chinese)李红山，冯琴，朱德东，等．瘦素在非酒精性脂肪性肝炎患者中的动态变化及中药干预作用[J]．中华中医药学刊，2013,31(9):1962-1964.

[34] FENG Q,LIU W,BAKER SS,et al. Multi-targeting therapeutic mechanisms of the Chinese herbal medicine QHD in the treatment of non-alcoholic fatty liver disease[J]. Oncotarget,2017,8(17):27820-27838.

[35] LI HS,FENG Q,XU LL,et al. Effects of Qushi Huayu Decoction in prevention and treatment of fatty liver in rats based on adiponection-free fatty acid pathway[J]. J Chin Integr Med,2009,7(6):546-551.(in Chinese)李红山，冯琴，许丽莉，等．祛湿化瘀方对脂肪肝大鼠脂联素-游离脂肪酸代谢路径的影响[J]．中西医结合学报，2009,7(6):546-551.

[36] FENG Q,MENG SX,TANG YJ,et al. Qushi Huayu Decoction inhibits hepatic lipid accumulation by activating AMP-activated protein kinase in experimental fatty liver of rats[J]. World Chin Med,2015,10(2):153-156.(in Chinese)冯琴，孟胜喜，唐亚军，等．祛湿化瘀方通过调节AMPK活性改善高脂饮食诱导的实验性脂肪肝肝脏脂肪代谢[J]．世界中医药，2015,10(2):153-156.

[37] YIN X,PENG J,ZHAO L,et al. Structural changes of gut microbiota in a rat non-alcoholic fatty liver disease model treated with a Chinese herbal formula[J]. Syst Appl Microbiol,2013,36(3):188-196.

[38] ZHANG Y,TANG K,DENG Y,et al. Effects of shenling baizhu powder herbal formula on intestinal microbiota in high-fat diet-induced NAFLD rats[J]. Biomed Pharmacother,2018,102:1025-1036.

[39] PORRAS D,NISTAL E,MARTNEZ-FLREZ S,et al. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation[J]. Free Radic Biol Med,2016,102:188-202.

[40] GUO Y,DING PH,LIU LJ,et al. Gegen qinlian decoction attenuates high-fat diet-induced steatohepatitis in rats via gut microbiota[J]. Evid Based Complement Alternat Med,2018,2018:7370891.

[41] LI ZH,ZHANG N,WANG Y,et al. Mechanism of action of Artemisia capillaris Thunb. decoction in treatment of nonalcoholic fatty liver disease:An analysis based on 16S rRNA technique and metabolomics[J]. China J Tradit Chin Med Pharma,2019,34(5):1908-1913.(in Chinese)李自辉，张娜，王宇，等．基于16S rRNA技术与代谢组学探究茵陈蒿汤治疗非酒精性脂肪肝的作用机制[J]．中华中医药杂志，2019,34(5):1908-1913.

[42] HE XY,HE JJ,ZHENG N,et al. Study on anti-obesity effect and modulation of gut microbiota by astragalus polysaccharides in mice[J]. World Chin Med,2016,11(11):2379-2384.(in Chinese)何旭云，贺姣姣，郑宁，等．黄芪多糖对肥胖小鼠的减肥作用与调节肠道菌群的关系研究[J]．世界中医药，2016,11(11):2379-2384.

[43] PENG JH,LENG J,TIAN HJ,et al. Geniposide and chlorogenic acid combination ameliorates non-alcoholic steatohepatitis involving the protection on the gut barrier function in mouse induced by high-fat diet[J]. Front Pharmacol,2018,9:1399.

[44] CHEN M,HOU P,ZHOU M,et al. Resveratrol attenuates high-fat diet-induced non-alcoholic steatohepatitis by maintaining gut barrier integrity and inhibiting gut inflammation through regulation of the endocannabinoid system[J]. Clin Nutr,2019.[Epub ahead of print]

[45] YANG JM,SUN Y,WANG M,et al. Regulatory effect of a Chinese herbal medicine formula on non-alcoholic fatty liver disease[J]. World J Gastroenterol,2019,25(34):5105-5119.

[46] ZHAO W,XIAO M,YANG J,et al. The combination of Ilexhainanoside D and ilexsaponin A1 reduces liver inflammation and improves intestinal barrier function in mice with high-fat diet-induced non-alcoholic fatty liver disease[J]. Phytomedicine,2019,63:153039.

施引文献

资源附件(0)

访问统计